↓ Skip to main content

High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease

Overview of attention for article published in Liver International, March 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#44 of 2,232)
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

twitter
23 tweeters

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease
Published in
Liver International, March 2018
DOI 10.1111/liv.13674
Pubmed ID
Authors

Faisal M. Sanai, Abdullah S. Alghamdi, Ahmad A. Afghani, Khalid Alswat, Adnan AlZanbagi, Mosfer N. Alghamdi, Abdallah AlMousa, Mohammed Aseeri, Abdullah M. Assiri, Mohamed A. Babatin

Abstract

Limited data has shown high efficacy of co-formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)-4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stage 4-5 (<30 mL/min/1.73 m2 ). We assessed real-world safety and efficacy of OBV/PTV/r ± DSV in GT1 and 4-infected patients. In this observational cohort (n=67), we enrolled stage 4-5 CKD treatment-naïve or Peginterferon/RBV-experienced GT4-infected patients (n=32) treated for 12-24 weeks with OBV/PTV/r ± RBV, and plus DSV in GT1 patients (n=35, including 3 with GT1/4 co-infection). RBV was dosed by physician discretion between 200 mg weekly - 200 mg daily. Primary endpoints were SVR12, calculated on intention-to-treat (ITT) basis, and occurrence of serious adverse events. The mean age of the cohort was 45.7±12.7 years, 50.7% were female, 20.9% had cirrhosis, 35.8% were treatment-experienced and 97% were on hemodialysis. Three patients (F4) received 24 weeks treatment, 2 with GT4, and 1 with GT1a; and 19.4% were treated without RBV, including 9 GT1, and 4 GT4. Overall, 65 (97.1%) patients achieved SVR12, including 100% of those with a post treatment follow-up (modified ITT analysis). Of the 2 patients without SVR12, one died from sepsis-related complications and the other from a myocardial infarction 2 weeks after completing therapy. Grade 3-4 anemia occurred in 8.9%. A 12-week regimen of OBV/PTV/r ± DSV with or without RBV is highly effective with a favourable safety profile amongst GT4 and GT1 patients with CKD stages 4-5. SVR12 rates were high regardless of patient characteristics. This article is protected by copyright. All rights reserved.

Twitter Demographics

The data shown below were collected from the profiles of 23 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 20%
Student > Bachelor 4 20%
Student > Master 2 10%
Student > Postgraduate 2 10%
Researcher 1 5%
Other 1 5%
Unknown 6 30%
Readers by discipline Count As %
Medicine and Dentistry 6 30%
Pharmacology, Toxicology and Pharmaceutical Science 3 15%
Agricultural and Biological Sciences 1 5%
Psychology 1 5%
Immunology and Microbiology 1 5%
Other 0 0%
Unknown 8 40%

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2018.
All research outputs
#1,302,627
of 17,053,340 outputs
Outputs from Liver International
#44
of 2,232 outputs
Outputs of similar age
#45,346
of 414,295 outputs
Outputs of similar age from Liver International
#1
of 67 outputs
Altmetric has tracked 17,053,340 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,232 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 414,295 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.